Results 131 to 140 of about 212,078 (304)

Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention [PDF]

, 2003
M. Hamon, S Fradin, A Denizet, E Filippi-Codaccioni, G Grollier, R Morello   +5 more
openalex   +1 more source

PB0041 Prevalence of Vascular Risk Factors and I/D Angiotensin-Converting Enzyme Gene (ACE) Polymorphism in Costa Rican Elderly Patients with Cognitive Impariment

, 2023
Lizbeth Salazar‐Sánchez, A. Kozakov-Valchuck   +1 more
openalex   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Dilation of forearm blood vessels after angiotensin-converting-enzyme inhibition by captopril in hypertensive patients. [PDF]

, 1984
D W Johns, C R Ayers, Scott C. Williams
openalex   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite

International Journal of Nanomedicine, 2012
Samer Hasan Hussein Al Ali1, Mothanna Al-Qubaisi2, Mohd Zobir Hussein1,3, Maznah Ismail2,4, Zulkarnain Zainal1, Muhammad Nazrul Hakim51Department of Chemistry, Faculty of Science, 2Laboratory of Molecular Biomedicine, Institute of Bioscience, 3Advanced ...
Hussein Al Ali SH, Al-Qubaisi M, Hussein MZ, Ismail M, Zainal Z, Hakim MN   +5 more
doaj  

Polymorphism of the angiotensin I-Converting enzyme gene in diabetic nephropathy in Type II diabetic patients with proliferative retinopathy [PDF]

, 1998
Osamu Hanyu, Haruo Hanawa, Osamu Nakagawa, Nagayuki Tani, Noburo Andou, Yoshifusa Aizawa, Akira Shibata   +6 more
openalex   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection [PDF]

, 2020
Josef Penninger, Maria B. Grant, Joseph J.�Y. Sung   +2 more
openalex   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source